Leerink Partnrs Increases Earnings Estimates for Cencora

Cencora, Inc. (NYSE:COR) – Equities researchers at Leerink Partnrs lifted their FY2026 EPS estimates for Cencora in a note issued to investors on Wednesday, November 6th. Leerink Partnrs analyst M. Cherny now expects that the company will post earnings per share of $17.08 for the year, up from their previous forecast of $16.44. The consensus estimate for Cencora’s current full-year earnings is $14.93 per share.

Several other research firms have also commented on COR. UBS Group boosted their price objective on Cencora from $275.00 to $285.00 and gave the stock a “buy” rating in a research note on Thursday, November 7th. Bank of America reissued a “neutral” rating and issued a $245.00 price objective (down from $275.00) on shares of Cencora in a research note on Wednesday, September 18th. JPMorgan Chase & Co. lifted their target price on shares of Cencora from $280.00 to $287.00 and gave the stock an “overweight” rating in a research note on Wednesday, August 21st. Wells Fargo & Company increased their target price on shares of Cencora from $236.00 to $249.00 and gave the company an “equal weight” rating in a research report on Thursday, August 1st. Finally, Barclays boosted their price target on shares of Cencora from $263.00 to $290.00 and gave the stock an “overweight” rating in a research report on Thursday, November 7th. Three research analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. According to data from MarketBeat, Cencora presently has a consensus rating of “Moderate Buy” and an average price target of $271.20.

Cencora Stock Up 0.3 %

COR stock opened at $249.09 on Monday. Cencora has a 52 week low of $191.11 and a 52 week high of $251.52. The company has a quick ratio of 0.55, a current ratio of 0.88 and a debt-to-equity ratio of 4.84. The firm has a 50-day simple moving average of $231.95 and a 200-day simple moving average of $230.74. The stock has a market capitalization of $49.08 billion, a P/E ratio of 33.17, a P/E/G ratio of 1.61 and a beta of 0.44.

Cencora Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, November 29th. Shareholders of record on Friday, November 15th will be given a $0.55 dividend. The ex-dividend date is Friday, November 15th. This represents a $2.20 dividend on an annualized basis and a yield of 0.88%. This is an increase from Cencora’s previous quarterly dividend of $0.51. Cencora’s payout ratio is currently 27.16%.

Insider Activity

In related news, Chairman Steven H. Collis sold 21,509 shares of the firm’s stock in a transaction dated Tuesday, October 22nd. The stock was sold at an average price of $235.80, for a total transaction of $5,071,822.20. Following the completion of the sale, the chairman now directly owns 285,088 shares of the company’s stock, valued at approximately $67,223,750.40. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 15.80% of the company’s stock.

Institutional Investors Weigh In On Cencora

A number of institutional investors have recently made changes to their positions in the stock. New Millennium Group LLC purchased a new position in shares of Cencora during the 2nd quarter worth approximately $26,000. TCTC Holdings LLC purchased a new position in shares of Cencora during the first quarter worth $29,000. TFO Wealth Partners LLC acquired a new stake in shares of Cencora in the first quarter valued at $30,000. MFA Wealth Advisors LLC purchased a new stake in shares of Cencora in the 2nd quarter valued at $30,000. Finally, Concord Wealth Partners acquired a new position in Cencora during the 3rd quarter worth about $30,000. 97.52% of the stock is currently owned by institutional investors and hedge funds.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.